This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today. 

The IRA requires drug companies to pay rebates to Medicare when prices for certain single-source and biosimilar prescription drugs covered under Part B increase faster than the rate of inflation. These 27 drugs are among the first rebatable drugs under the law. Part B drugs impacted by a coinsurance adjustment may change quarterly. For more information, see the CMS fact sheet.

Related News Articles

Headline
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…
Headline
The Centers for Medicare & Medicaid Services June 28 released a proposed rule on mitigating the impact of significant, anomalous and highly suspect (SAHS)…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Perspective
For too long and for too many patients, the process of obtaining prior authorization for a medical procedure or medicine has been a tangled web, as people are…
Headline
The AHA June 14 sent a letter to the Senate Finance Committee, responding to questions included in a white paper the committee wrote on chronic care through…
Headline
The Centers for Medicare & Medicaid Services estimates national health spending grew 7.5% in 2023, reflecting increases in insurance growth, the agency…